No Data
Express News | Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
Wells Fargo Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $58
Wells Fargo analyst Yanan Zhu maintains $Arcturus Therapeutics(ARCT.US)$ with a buy rating, and sets the target price at $58.According to TipRanks data, the analyst has a success rate of 36.4% and a t
Piper Sandler Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $140
Piper Sandler analyst Yasmeen Rahimi maintains $Arcturus Therapeutics(ARCT.US)$ with a buy rating, and maintains the target price at $140.According to TipRanks data, the analyst has a success rate of
Buy Rating for Arcturus Therapeutics: Advancing Clinical Programs and Strengthening Safety Profile
Piper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Arcturus Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Arcturus Therapeutics Price Target Maintained With a $60.00/Share by HC Wainwright & Co.